What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence from the KEYNOTE-091 phase 3 trial demonstrates a clear clinical advantage for pembrolizumab over placebo, with statistically significant improvements in disease-free survival (DFS) and overall survival (OS) for both the full licensed population and the PD-L1 TPS less than 50% subgroup. The hazard ratios indicate a meaningful reduction in the risk of recurrence, supporting the conclusion that pembrolizumab provides a significant therapeutic benefit.
Does the economic case hold at the expected price? — Cost effectiveness
The committee concluded that the most likely cost-effectiveness estimate for pembrolizumab falls within the range considered acceptable by NICE. The economic model supports its use as a cost-effective treatment option, particularly given the unmet need in the specified population.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document does not provide specific HRQoL data, it implies that pembrolizumab may alleviate anxiety related to cancer recurrence, which could positively impact quality of life. However, the absence of direct evidence on validated HRQoL measures limits the rating to B++.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Pembrolizumab has an acceptable safety profile, with adverse events primarily being mild to moderate. The document indicates that serious adverse events are rare, supporting a good tolerability profile compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator for pembrolizumab is active monitoring, which is appropriate given the treatment context. However, the exclusion of other potential comparators like atezolizumab and osimertinib raises concerns about the comprehensiveness of the comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is largely representative of the intended patient population, with subgroup analyses conducted for those with PD-L1 TPS less than 50%. However, the reliance on post hoc analyses for some subgroups introduces some limitations.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Pembrolizumab can be integrated into existing care pathways with minor adjustments, as it follows standard treatment protocols for NSCLC. The document indicates that no significant new infrastructure or training is required for its implementation.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of pembrolizumab are manageable, with the potential for cost savings in the long term due to reduced recurrence rates. The economic model suggests that the budget impact is justifiable given the expected health outcomes.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is strong, primarily derived from a phase 3 RCT with a large sample size. However, some concerns regarding the post hoc analyses and the reliance on surrogate endpoints for long-term outcomes introduce a degree of uncertainty.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness and cost-effectiveness of pembrolizumab, particularly related to the assumptions made in the economic model. The committee acknowledged these uncertainties but deemed them manageable.
